MeSH note : drug immunoconjugate composed of doxorubicin conjugated to the humanized anti-CD74
monoclonal antibody, hLL1, at a doxorubicin/monoclonal antibody ratio of approximately
8:1 (mol/mol); the excellent safety and efficacy profile of IMMU-110 supports clinical
testing of this immunoconjugate in the treatment of CD74-positive B-cell malignancies;